

## Regulatory Announcement

For immediate release

17 August 2007

**PROXIMAGEN NEUROSCIENCE PLC**  
("Proximagen" or "the Company")  
**Disclosure of Information Required by AIM Rule 26**

Proximagen Neuroscience plc (AIM: PRX), the drug discovery and development company focused on neurodegenerative diseases, is pleased to announce that its website is now compliant with Rule 26 of the AIM Rules for Companies.

This information can be viewed within the investor relations section of the Company's website at the following address: [www.proximagen.com/rule26.shtml](http://www.proximagen.com/rule26.shtml).

**For more information please contact:**

**Proximagen**

Ken Mulvany, Chief Executive

020 7848 6011

**Buchanan Communications**

Tim Anderson, Mary-Jane Johnson, Catherine  
Breen

020 7466 5000